InSilico Medicine Cayman TopCo Stock: price and insider trades · Hong Kong
1 insider bought €610k of shares over the last 90 days, the latest by ZAVORONKOVS Aleksandrs, filed 10 Sept 2026.
InSilico Medicine Cayman TopCo: what insiders have been doing
InSilico Medicine Cayman TopCo is a Health Care company. Its directors and officers file their transactions with HKEX. Over the twelve months to 22 October 2026, 7 filings were filed, from 2 insiders.
Both sides are active: 2 purchases worth €610k and 1 sale, from 1 insider and 1 insider respectively. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €497k from ZAVORONKOVS Aleksandrs, disclosed on 9 September 2026, or 0.019% of market capitalisation. Among those who bought: 1 senior executive.
The last purchase on record was published on 10 September 2026, which is 59 days ago. Filings reach the HKEX feed a median of 5 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.
With 7 filings in twelve months, the company is more active than the median of 4 filings across the 1,314 companies we follow on the same exchange. Our records for InSilico Medicine Cayman TopCo go back to 2026, with 2 purchases and 1 sale on the open market in total.
Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -28.7%Entry HK$50.50 · Close 22 Oct 2026 HK$36.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 266,678 sharesShareXHKGHKEX:DA20261013E00535
- 21,000 shares@ HK$48.760.0044% mcap18.4% of flowShareXHKGHKEX:DA20260910E00081Canonical exit: 6 Dec 2026 (T+90)
- 92,500 shares@ HK$48.98780.019% mcap81.6% of flowShareXHKGHKEX:DA20260909E00359Canonical exit: 3 Dec 2026 (T+90)
- 787,265 sharesShareXHKGHKEX:DA20260706E00795
- 1,599,920 sharesShareXHKGHKEX:DA20260706E00794
- 8,740,820 sharesShareXHKGHKEX:DA20260112E00635
- 46,643,500 sharesShareXHKGHKEX:DA20260112E00634
7 of 7 declarations
About InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo is a company focused on developing artificial intelligence solutions for drug discovery. It operates on the Hong Kong market.
